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T  lymphocytes expressing the γδ T  cell receptor (γδ TCR) can recognize antigens 
expressed by tumor cells and subsequently kill these cells. γδ T cells are indeed used 
in cancer immunotherapy clinical trials. The anti-CD3ε antibody UCHT1 enhanced the 
in vitro tumor killing activity of human γδ T cells by an unknown molecular mechanism. 
Here, we demonstrate that Fab fragments of UCHT1, which only bind monovalently 
to the γδ TCR, also enhanced tumor killing by expanded human Vγ9Vδ2 γδ T cells or 
pan-γδ T cells of the peripheral blood. The Fab fragments induced Nck recruitment to 
the γδ TCR, suggesting that they stabilized the γδ TCR in an active CD3ε conformation. 
However, blocking the Nck-CD3ε interaction in γδ T cells using the small molecule inhib-
itor AX-024 neither reduced the γδ T cells’ natural nor the Fab-enhanced tumor killing 
activity. Likewise, Nck recruitment to CD3ε was not required for intracellular signaling, 
CD69 and CD25 up-regulation, or cytokine secretion by γδ T cells. Thus, the Nck-CD3ε 
interaction seems to be dispensable in γδ T cells.
Keywords: γδ T cells, T cell antigen receptor, tumor, nck, activation, signaling, Fab fragments, aX-024
inTrODUcTiOn
T cells are part of the adaptive immune system and can be divided into αβ and γδ T cells, depending on 
the T cell antigen receptor (TCR) they express. Whereas most αβ TCRs recognize peptides presented 
by MHC molecules, γδ TCRs recognize stress-induced self-antigens (1, 2), lipids or pyrophosphates 
that are secreted by microbes or overproduced in tumor cells (3–7).
The main subset of γδ T  cells in human blood is Vγ9Vδ2, which accounts for 2–10% of all 
T cells. The Vγ9Vδ2 TCR recognizes self and foreign non-peptidic phosphorylated small organic 
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compounds of the isoprenoid pathway, collectively termed 
phosphoantigens (8–12). It is known that Vγ9Vδ2 T  cells are 
also stimulated by certain tumor cells, such as the Daudi B cell 
lymphoma (13), which most likely expresses high levels of phos-
phoantigens (14). Alternatively, γδ T cells recognize cell surface 
molecules that are differentially expressed on transformed solid 
tumors or lymphomas and leukemias (7, 15). An enhanced pro-
duction of phosphoantigens in transformed cells can be further 
increased by therapeutically administered nitrogen-containing 
bisphosphonates, such as zoledronate, which inhibit the farnesyl 
pyrophosphate synthase of the isoprenoid pathway (16, 17). 
Several studies demonstrated that a repetitive stimulation of γδ 
T cells in vivo is necessary to reduce tumor growth (18–20). While 
sustained stimulation of Vγ9Vδ2 γδ T cells by phosphoantigens 
or nitrogen-containing bisphosphonates often leads to their 
exhaustion, bispecific antibodies provide a newly tool to target 
γδ T  cells to antigens expressed by tumor cells and enhanced 
their cytotoxic activity (19, 21–23). Although the exact molecular 
mechanism leading to phosphoantigen recognition is a matter of 
debate (24, 25), this recognition is clearly mediated by cognate 
interaction with the Vγ9Vδ2 TCR.
T  cell antigen receptors consist of a clonotypic TCRαβ or 
TCRγδ heterodimer, and the CD3δε, CD3γε, and CD3ζζ dimers. 
TCRαβ and TCRγδ bind to the antigen and the CD3 chains 
transduce the signal of antigen binding into the cell by phospho-
rylation of the tyrosines in their cytoplasmic tails by Src-family 
kinases. Consequently, the tyrosine kinase ZAP70 can bind to 
phosphorylated CD3 and the signal of ligand binding is transmit-
ted further to intracellular signaling cascades, such as Ca2+ influx 
and the Ras/Erk pathway, ultimately resulting in the activation of 
the T cell. This includes the execution of the cytotoxic activity to 
kill infected or tumor cells, up-regulation of CD69 and CD25, as 
well as secretion of cytokines.
How antigen binding to the TCR is communicated to the cyto-
solic tails of CD3 is not well understood. The αβ TCR is in equilib-
rium between two reversible conformations: the antigen-stabilized 
active CD3 conformation and the resting conformation adopted 
by non-engaged TCRs (26–28). The active CD3 conformation is 
stabilized by peptide-MHC or anti-CD3 antibody binding to the 
αβ TCR (29, 30), and it is absolutely required (but not sufficient) 
for TCR activation (27, 30–32). This active CD3 conformation is 
defined by the exposure of a proline-rich sequence (PRS) in CD3ε 
that then binds to the SH3.1 domain of the adaptor protein Nck 
[SH3.1(Nck)] (26, 33). Blocking the CD3ε–Nck interaction by the 
small molecule inhibitor AX-024 or by other means diminished 
ligand-induced CD3 phosphorylation and downstream signal-
ing events (34–36). Shifting to the active CD3 conformation is 
necessary for αβ TCR triggering, however, it is not sufficient 
(30, 37). Fab fragments of anti-CD3 antibodies stabilize the active 
conformation, but are unable to elicit biochemical signals leading 
to T cell activation (30, 38, 39). In addition, antigen-induced αβ 
TCR clustering and/or phosphatase exclusion are required, most 
likely to elicit stable phosphorylation of the ITAMs and thus, 
T cell activation (30, 37, 40).
How antigen binding to the γδ TCR is transmitted to the 
cytosolic tails of CD3 is even more obscure. Antigen binding 
to TCRγδ failed to expose the CD3ε’s PRS, in sharp contrast to 
the αβ TCR, but efficiently activated the γδ T cell (41). Artificial 
induction of the active conformation by binding the anti-CD3ε 
antibody UCHT1 to the γδ TCR enhanced the cytotoxic activity 
of human γδ T  cells against a pancreatic tumor cell line (41). 
Whether Nck is recruited to γδ TCRs in the natural or the UCHT1 
enhanced activity and whether this plays a role in the increased 
tumor killing is to date unknown.
Here, we used expanded γδ T  cells from human peripheral 
blood of healthy donors and show that UCHT1 and Fab frag-
ments of UCHT1 lead to the recruitment of Nck to the γδ TCR. 
Further, we stimulated the γδ T cells with B cell lymphomas and 
demonstrate that UCHT1 Fab fragments increase the tumor kill-
ing by the γδ T cells and that Nck binding to the γδ TCR is not 
involved in this tumor killing.
MaTerials anD MeThODs
expansion of human γδ T cells
Informed consent for the performed studies was obtained from 
the donors in accordance with the Declaration of Helsinki and 
Institutional Review Board approval from the University of 
Freiburg Ethics Committee (412/9). Human peripheral blood 
mononuclear cells were isolated from healthy donors by using a 
Ficoll–Hypaque gradient. Cells were adjusted to 106 cells/ml and 
cultured in RPMI 1640 supplemented with 10% fetal calf serum 
(FCS) and antibiotics.
To expand Vγ9Vδ2 γδ T  cells, cells were stimulated with 
2.5 µM zoledronate and 50 U/ml rIL-2 (Novartis). Additionally, 
rIL-2 was added every 2 days over a culture period of 21 days. 
After 14 days the purity of expanded γδ T cells was analyzed by 
flow cytometry and was >95% Vγ9Vδ2 T cells.
To expand different γδ T  cell subsets, cells were stimulated 
with 1 µg/ml concanavalin A and rIL-2 and rIL-4 (both 100 U/ml) 
were added to the cell suspensions. Additionally, rIL-2 and IL-4 
were added every 3–4 days over a culture period of 21 days. After 
14 days γδ T cells were enriched by negative isolation using the 
human TCRγ/δ+ T Cell Isolation Kit (Miltenyi Biotech). Cultures 
were composed of 20–40% Vδ1+ and 60–80% Vδ2+ T cells and the 
purity of the enriched γδ T cells was evaluated by flow cytometry. 
Cultures with a purity >95% were used for the experiments.
51cr release assay
Daudi or Raji tumor cells (5,000 cells/well in a 96-well plate) were 
incubated with 50  µl 51Cr for 1  h at 37°C. After labeling, cells 
were washed two times and the cell concentration was adjusted to 
5 × 104 cells/ml in RPMI 1640 supplemented with 10% FCS, anti-
biotics, and 50 U/ml rIL-2 (Novartis). The assay was performed in 
U bottom 96-well plate, with an effector (γδ T cell) to target (Daudi 
or Raji cells) ratio of 12.5:1, in triplicates and with six replicates 
for spontaneous (51Cr release from target cells in medium alone) 
and maximum release (51Cr release from target cells lysed with the 
detergent Trition X-100). The required amount of effector cells 
(6.25 × 104 cells/well) was harvested and the concentration was 
adjusted to 1.25 × 106 cells/ml in RPMI 1640 supplemented with 
10% FCS and 50  U/ml rIL-2 (Novartis). To the labeled tumor 
cells the expanded γδ T cells were added, and left untreated (−) 
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or treated with 5 µg/ml UCHT1, 3.33 µg/ml Fab, or 3.33 µg/ml 
Fabred (to obtain equimolar amounts). Additionally, DMSO or 
different concentrations of the inhibitor AX-024 (36) solubilized 
in DMSO were added. Cells were incubated at 37°C and 5% CO2 
for 5 h. After incubation, 50 µl of the supernatant was transferred 
into 51Cr filter plates (Lumaplate). The plates were measured in a 
microplate scintillation γ-ray counter and data were acquired in 
counts per minute (cpm). Cytotoxicity was calculated according 
to the formula: specific lysis (%) = (experimental cpm − sponta-
neous cpm): (maximum cpm − spontaneous cpm) × 100.
sh3.1(nck) Pull Down assay
Zoledronate-expanded γδ T  cells were starved for 1  h at 37°C 
in RPMI 1640 without FCS and left unstimulated or stimulated 
with 5  µg/ml anti-CD3 antibody UCHT1. Cells were lysed in 
lysis buffer containing 20  mM Tris–HCl pH 8, 137  mM NaCl, 
2  mM EDTA, 10% glycerol, protease inhibitor cocktail, and 
0.3% Brij96V. Subsequently, insoluble material was removed by 
centrifugation. Postnuclear fractions were incubated with glu-
tathione beads coupled to GST-SH3.1(Nck) at 4°C as described 
(26). Beads, including the bound proteins, were washed and 
proteins separated by non-reducing SDS-PAGE. Western blotting 
was performed with anti-CD3ζ and anti-GST antibodies.
Preparation of Fab and Fabred Fragments
UCHT1 Fab fragments were prepared using the Pierce® Fab 
Micro Preparation Kit from Thermo Fisher Scientific, which uses 
the enzyme papain to cleave the complete UCHT1 antibody and 
protein A coupled beads to purify the Fab fragments. The purified 
Fab fragments were analyzed by SDS-PAGE and Coomassie stain-
ing. To generate reduced Fab fragments (Fabred) the purified Fab 
fragment was incubated with 10 mM dithiothreitol for 30 min at 
room temperature. Afterward, 1 mM iodoacetamide was added 
and incubated for further 30 min at room temperature. The Fabred 
were then immediately used. Purity of Fab and Fabred was further 
tested by their inability to induce Ca2+ influx in T cells.
Flow cytometry
Concanavalin A expanded γδ T cells were incubated with 5 µg/ml 
UCHT1, 3.33 µg/ml Fab, or 3.33 µg/ml Fabred or left untreated 
at 37°C and 5% CO2 for 5 h. Cells were washed two times and 
stained with APC-labeled anti-mouse IgG antibody on ice 
(Southern Biotech). The labeled cell suspension was analyzed by 
the Gallios™ flow cytometer and the data were analyzed with 
FlowJo software.
Jurkat and G8 γδ TCR-expressing Jurkat cells were stained 
with APC-labeled anti-mouse γδ TCR (GL3; eBioscience). Cells 
were analyzed as described above.
Measurement of ca2+ influx
Five million cells were resuspended in 1 ml RPMI 1640 medium 
supplemented with 1% FCS in the presence or absence of 
10  nM AX-024, antibiotics, and labeled in the dark with 0.1% 
pluronic acid, 2.6 µM Fluo-3 AM, and 5.5 µM Fura Red AM (Life 
Technologies) for 45 min at 37°C. The stained cells were washed 
and kept on ice in the dark until the measurement. For calcium 
influx, cells were diluted 1:20 with pre-warmed medium and 
maintained at 37°C during the event collection on a CyAn ADP 
flow cytometer (Beckman Coulter). Baseline fluorescence was 
monitored for 1.5 min, then the stimuli were added as indicated 
(the Fab and Fabred fragments were added 30 s earlier to ensure 
binding to the γδ TCR when the other stimuli were added). The 
stimulation was recorded for further 5 min. Data were analyzed 
with the FlowJo software.
intracellular staining for Phospho-ZaP70 
and Phospho-erk
Peripheral blood mononuclear cells were isolated from healthy 
donors using a Ficoll–Hypaque gradient. T cells were obtained 
by negative isolation using the Pan T cell Isolation Kit (Miltenyi 
Biotech). Cells were taken in RPMI 1640 supplemented with 10% 
FCS and were rested for 1 h at 37°C in the presence or absence 
of different concentrations of the inhibitor AX-024 (36). Cells 
were left unstimulated or stimulated with 10  µg/ml anti-CD3 
antibody UCHT1 for 2  min or 5  min and were fixed with 2% 
paraformaldehyde for 30  min on ice. Subsequently, cells were 
permeabilized with 87.7% methanol for 30  min on ice and 
stained with rabbit anti-phospho-ZAP70 (Cell Signaling) or 
rabbit phospho-Erk (Cell Signaling) overnight. Next, cells were 
stained  with biotin-labeled anti-CD3 (UCHT1; BioLegend), 
PE-labeled anti-γ/δTCR antibodies (Life Technologies), and 
DyLight-labeled anti-rabbit IgG (Thermo Scientific) and sub-
sequently with eFluor 450-labeled Streptavidin (eBioscience). 
Cells were measured by flow cytometry and gated on CD3- and 
TCRγδ-positive cells for analysis.
In Situ Proximity ligation assay (Pla)
Cells were grown on diagnostic microscopic slides (Thermo 
Scientific). They were left unstimulated, stimulated with 5 µg/ml 
UCHT1, 3.33 µg/ml Fab, or 3.33 µg/ml Fabred and simultaneously 
treated with 10 nM AX-024 at 37°C for 5 min. Cells were then 
fixed with 4% paraformaldehyde, permeabilized with 0.5% sapo-
nin, and blocked with blocking solution. Subsequently, cells were 
co-incubated with the goat anti-CD3ε (M20ε, Santacruz) and 
a rabbit anti-Nck1 antibody (Cell Signaling). PLA between the 
CD3ε and Nck1 molecules was performed with the Duolink kit 
according to the manufacturer’s instructions (Olink Bioscience), 
resulting in red fluorescence signals. Cell nuclei were stained with 
DAPI. A confocal microscope (C2, Nikon) was used for imaging 
and analysis. The number of the PLA signal dots was scored with 
the BlobFinder program (Uppsala University).
cD25 and cD69 Up-regulation
To each well of a U bottom 96-well plate 2 × 104 Daudi or Raji 
tumor cells, 2.5 × 105 expanded γδ T cells, and 5 µg/ml UCHT1, 
3.33 µg/ml Fab, 3.33 µg/ml Fabred, or medium (unstimulated) were 
given. In addition, the cells were left untreated or treated with dif-
ferent concentrations of AX-024. The plate was incubated at 37°C 
and 5% CO2 for 18 h. After incubation, the supernatants were kept 
at −80°C to quantify the amounts of TNFα and IFNγ (see below). 
Cells were stained with APC-labeled anti-CD25 (eBioscience) 
or APC-labeled anti-CD69 (Life Technologies) together with 
PE-labeled anti-γ/δTCR antibodies (Life Technologies). Cells 
were analyzed by flow cytometry gating on γδTCR-positive cells.
FigUre 1 | UCHT1 increased tumor killing by γδ T cells. 51Cr-labeled Daudi 
and Raji cells were incubated with zoledronate-expanded human γδ T cells 
without (−) or with the addition of 5 µg/ml UCHT1 using an effector to target 
(T cell to tumor cell) ratio of 12.5:1. After 5 h of co-culture, the amount of 
released 51Cr was measured in the supernatant by γ-ray spectroscopy. Data 
represent mean ± SD of triplicate wells (n = 3). Significance was determined 
by unpaired t-test, two-tailed between untreated γδ T cells and treated 
samples.
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TnFα and iFnγ secretion
The concentrations of TNFα and IFNγ in the culture supernatants 
were measured by standard enzyme linked immunosorbent assay 
(ELISA).
statistical analysis
Data are represented as mean ±  SEM or ±  SD. All differences 
between experimental groups were analyzed with the Student’s 
t-test. Significant differences were considered when the p values 
were less than 0.05. (n.s. = non significant, *p < 0.05, **p < 0.01, 
***p  <  0.001, and ****p  <  0.0001). n refers to the number of 
independently performed experiments.
resUlTs
The anti-cD3ε antibody UchT1 enhances 
Tumor Killing by human γδ T cells
Human short-term expanded Vγ9Vδ2 γδ T cells can kill pancre-
atic ductal adenocarcinoma Panc89 cells in vitro (21, 23), which 
was enhanced by co-incubation with the anti-CD3ε antibody 
UCHT1 (41). In order to test target cells from different origins, we 
used now the 51Cr-labeled human B cell lymphoma lines Daudi 
or Raji (13) and incubated them with zoledronate-expanded 
peripheral blood human γδ T  cells in the presence or absence 
of UCHT1. Release of 51Cr to the cell culture supernatant is a 
measure for the lysis of the tumor cells and was quantified with a 
scintillation γ-ray counter. Approximately 40% of the Daudi and 
5% of the Raji cells were specifically killed by the γδ T cells in 
the absence of exogenously added antibody (Figure 1). The addi-
tion of the UCHT1 antibody strongly enhanced tumor killing by 
the γδ T cells reaching 75% of specific killing for both cell lines 
(Figure 1).
Using its sh3.1(nck) Domain, nck is 
recruited to the UchT1-stimulated γδ 
Tcr
UCHT1 stabilizes the γδ TCR in the active CD3 conformation, 
in which the CD3ε PRS is exposed (41). Since only the exposed 
PRS binds to SH3.1(Nck), PRS exposure can be measured with 
the SH3.1(Nck) pull down assay (Figure  2A). To test whether 
the UCHT1-bound γδ TCR can bind to SH3.1(Nck) in our zole-
dronate-expanded γδ T cells, we incubated the cells with or with-
out UCHT1 and lysed them. Performing a pull down assay using 
SH3.1(Nck)-coupled beads, we found that UCHT1 increased 
the amount of γδ TCR that bound to the beads (Figures 2B,C). 
This indicated that SH3.1(Nck) can bind to the γδ TCR and that 
UCHT1 stabilizes the γδ TCR in the active CD3 conformation.
To date it is unknown whether endogenous Nck is recruited 
to the γδ TCR upon stimulation. To test this, we used the in situ 
PLA. PLA is a technique that allows visualization of the close 
proximity between endogenous proteins in fixed cells by a red 
fluorescent dot (42). Recently, we established the PLA to quantify 
the proximity of Nck with the αβ TCR using anti-CD3ε and anti-
Nck antibodies (33). Here we applied this assay to γδ T cells. To 
this end, we incubated expanded human γδ T cells with UCHT1 
and performed PLA (Figure 2D). Indeed, CD3ε–Nck proximity 
was increased in UCHT1-stimulated cells compared to unstimu-
lated cells (Figures 2E,F) suggesting that Nck is indeed recruited 
to the γδ TCR upon UCHT1 binding.
To test whether endogenous Nck uses its SH3.1 domain to 
bind to the CD3ε PRS in the γδ TCR, we made use of the small 
molecule inhibitor AX-024. In αβ T cells AX-024 was shown to 
specifically bind to SH3.1(Nck) and hence block the SH3.1(Nck)–
PRS interaction (36). Using αβ T  cells as a control, we made 
sure that PLA is a suitable assay to test the inhibition of the 
SH3.1(Nck)–PRS interaction mediated by AX-024 (Figure S1 in 
Supplementary Material). Next, we incubated the γδ T cells with 
UCHT1 in the absence or presence of 10 nM AX-024. Indeed, 
the CD3ε–Nck proximity was reduced to background levels after 
AX-024 treatment (Figures 2E,F), indicating that the PRS–SH3.1 
interaction is necessary for the recruitment of Nck to the γδ TCR 
upon UCHT1 binding. This finding was corroborated with a PLA 
experiment in which CD3 phosphorylation was blocked using the 
Src kinase inhibitor PP2 (Figure S2 in Supplementary Material). 
Indeed, Nck was recruited to the γδ TCR in the presence of PP2, 
suggesting that an SH2(Nck)-phospho-CD3 interaction was not 
required.
Preparation of Pure UchT1 Fab 
Fragments
Complete anti-CD3ε antibodies bind bivalently to the TCR 
leading to T cell activation, whereas Fab fragments of the same 
antibodies bind monovalently and fail to activate T  cells (30, 
37–39). The use of complete anti-CD3ε antibodies in therapeu-
tical settings might have the drawback of unspecific polyclonal 
T  cell activation. Thus, we aimed here to investigate whether 
UCHT1 Fab fragments that only bind monovalently to the 
TCR might enhance tumor killing by human γδ T cells in the 
absence of undesired unspecific T cell activation. To this end, 
FigUre 2 | Using its SH3.1(Nck) domain Nck binds to the UCHT1-stimulated γδ T cell antigen receptor (TCR). (a) Schematic of the SH3.1(Nck) pull down assay. 
(B) Zoledronate-expanded γδ T cells were left untreated (−) or stimulated with 5 µg/ml UCHT1 at 37°C for 5 min. The cellular lysates were incubated with 
SH3.1(Nck)-coupled beads and bound proteins separated by SDS-PAGE along with aliquots of the cellular lysate. Western blotting was done using anti-CD3ζ and 
anti-GST antibodies. (c) The normalized ratio of the band intensities of CD3ζ to GST in the SH3.1(Nck) pull down is plotted. Data of three independent experiments 
were used to calculate the mean ± SD; statistics was done by two-tailed t-test. (D) Schematic of the in situ proximity ligation assay (PLA) using anti-CD3ε and 
anti-Nck antibodies. (e) Close proximity between the TCR and Nck was detected by in situ PLA. Zoledronate-expanded γδ T cells were either left untreated (−) or 
treated with 5 µg/ml UCHT1 in the absence or presence of 10 nM AX-024 at 37°C for 5 min. After fixation and permeabilization, PLA was performed using the 
primary antibodies goat anti-CD3ε (M20) and rabbit anti-Nck1, and the corresponding secondary antibodies. Nuclei were stained with DAPI. (F) The corresponding 
quantification of the red PLA dots and the mean ± SEM is displayed; statistics was done by two-tailed t-test. For each condition 500 cells were analyzed.  
Three independent experiments were performed (n = 3).
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we generated pure Fab fragments by cleaving UCHT1 antibod-
ies with papain and subsequently purifying the Fab fragments 
using the Pierce Fab Micro Preparation kit. The complete 
UCHT1 antibody before and after digestion and the purified 
Fab fragments were analyzed by reducing SDS-PAGE and 
Coomassie staining (Figure 3A). We found that the complete 
immunoglobulin heavy chain (HC) at 50 kDa was not detectable 
in the Fab fragments, but the light chain (LC) was traceable at 
24 kDa (lane 4). As the variable and CH1 parts of the HC have 
the same size as the LC, they are not visible as an additional band 
in SDS-PAGE (Figure 3A, Fab).
We found earlier that very small amounts of F(ab′)2 fragments 
might contaminate the Fab preparation. They are not detectable 
by SDS-PAGE and Coomassie staining, but due to their cross-
linking ability they can lead to TCR activation in functional assays 
(30). F(ab′)2 fragments can be reduced to Fab fragments by the 
use of dithiothreitol (DTT) followed by quenching of DTT with 
iodoacetamide (30). To test for the presence of small amounts 
of contaminating UCHT1 or UCHT1 F(ab′)2 fragments in the 
Fab preparation, we incubated our reagents with TCRαβ-negative 
Jurkat T cells expressing the human Vγ9Vδ2 TCR (43, 44) and 
measured calcium influx into the cytosol as a read-out for TCR 
activity. The unreduced Fab fragments either did not induce any 
or just a very small increase in cytosolic calcium (Figure 3B, upper 
panel), indicating that some preparations were contaminated with 
tiny amounts of F(ab′)2. However, the reduced Fab fragments 
never induced any calcium response (Figure 3B, second panel). 
As a control, the reduced Fab fragment cross-linked by anti-κ LC 
antibodies, resulted in calcium influx, indicating that the reduced 
Fab fragments were functional. Treatment of the cells with the 
complete UCHT1 antibody resulted in the strongest calcium 
response (Figure 3B, lowest panel). From now on, UCHT1 Fab 
fragments will be called “Fab” and the reduced fragments “Fabred.”
By using staining and flow cytometry, we show that Fab and 
Fabred can equally well bind to human γδ T cells (Figure 3C).
In conclusion, Fabred preparations contained functional Fab 
fragments that are purely monovalent and failed to crosslink and 
activate the TCR.
FigUre 3 | Preparation of UCHT1 Fab fragments. (a) The anti-CD3ε antibody UCHT1 was digested with papain using a kit from Thermo Fisher Scientific. The Fab 
fragments were purified with protein A coupled beads. The complete antibody (lane 1), the first and second digestions (lanes 2 and 3), and the purified Fab fragment 
(lane 4) were separated by reducing SDS-PAGE followed by Coomassie staining (n > 3). (B) Jurkat Vγ9Vδ2 cells were labeled with Fluo-3 AA and Fura Red AM and 
the baseline of cellular Ca2+ was measured by flow cytometry for 1 min. The indicated reagents were then added and Ca2+ levels were measured for additional 6 min 
(black lines). The gray lines represent baseline Ca2+ level without addition of any stimuli (n > 3). (c) Concanavalin A expanded γδ T cells were stained with UCHT1, 
Fab, Fabred, or left untreated, followed by an APC-labeled anti-mouse IgG antibody as a secondary reagent. Fluorescence intensities were quantified by flow 
cytometry (n > 3).
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UchT1 Fab Fragments enhance Tumor 
Killing by human γδ T cells
Next, we tested whether Fab and Fabred enhance tumor killing 
by γδ T cells. To this end, we co-cultured zoledronate-expanded 
γδ T cells with Daudi or Raji cells as in Figure 1. Both, Fab and 
Fabred increased killing of the tumor cells (Figure 4A). In Daudi 
cells, which were more susceptible to the cytotoxic activity of the 
γδ T cells, Fab, and Fabred were almost as active as UCHT1. In 
Raji cells, which were only killed to 5% by γδ T cells, Fab and 
Fabred enhanced the cytotoxic activity, so that 30% of the cells were 
killed.
Zoledronate and IL-2 specifically expand human Vγ9Vδ2 γδ 
T cells (16, 23). γδ T cells can also be expanded from human 
peripheral blood using the lectin concanavalin A, IL-4, and 
IL-2, resulting in cultures containing both, Vδ1 and Vδ2 γδ 
T cells (45). Concanavalin A, IL-4, and IL-2 expanded γδ T cells 
(here called concanavalin A expanded γδ T  cells) also killed 
Daudi and Raji cells, and this activity was increased by UCHT1, 
Fab, and Fabred (Figure 4B). This effect was not donor-specific, 
since the enhanced tumor killing mediated by UCHT1, Fab, and 
Fabred was also observed when using concanavalin A expanded 
γδ T  cell from blood of four different healthy donors (HD, 
Figure 4C).
nck is recruited to the γδ Tcr Upon 
Binding to Fab and Fabred
Fab and Fabred do not cross-link the γδ TCR, but might enhance 
tumor killing by stabilizing the active CD3 conformation of the 
γδ TCR—just as the complete UCHT1 antibody does (Figure 2). 
Hence, we used PLA to test whether Fab and Fabred induced the 
recruitment of Nck to the γδ TCR. Indeed, treatment of the γδ 
T cells with Fab and Fabred resulted in an increase in TCR–Nck 
proximity (Figures 5A,B). Again, the incubation with the small 
molecule inhibitor AX-024 reduced Nck binding to the γδ TCR 
to background levels. This finding suggests that binding of Fab 
and Fabred to the γδ TCR artificially stabilizes the active CD3 
conformation and results in the recruitment of Nck to the γδ TCR 
using the SH3.1(Nck) domain.
Tumor Killing by γδ T cells is independent 
of nck recruitment to the γδ Tcr
We next analyzed whether Nck recruitment to the γδ TCR upon 
UCHT1, Fab, or Fabred treatment was involved in γδ T cell activa-
tion mediated by tumor cells, and for the cytotoxic activity of 
γδ T cells. Concanavalin A expanded γδ T cells (Figure 6A) or 
zoledronate-expanded γδ T cells (Figure 6B) were incubated with 
FigUre 5 | UCHT1 Fab induced the recruitment of Nck to the γδ T cell antigen receptor. (a) The proximity ligation assay as in Figure 2 was performed using  
5 µg/ml UCHT1, 3.33 µg/ml Fab, and 3.33 µg/ml Fabred in the absence or presence of 10 nM AX-024. (B) The data of (a) were analyzed as in Figure 2F; 700 cells 
were analyzed per condition. Two independent experiments were performed (n = 2).
FigUre 4 | Fab and Fabred fragments enhanced tumor killing by γδ T cells. 51Cr-labeled Daudi and Raji cells were incubated with zoledronate (a) or concanavalin A 
(B) expanded γδ T cells in triplicates without (−) or with 5 µg/ml UCHT1, 3.33 µg/ml Fab, or 3.33 µg/ml Fabred (these concentrations were chosen to obtain 
equimolar amounts of the different reagents). The effector to target ratio was 12.5:1. After 5 h of co-culture, the amount of released 51Cr was measured in the 
supernatant by γ-ray spectroscopy (n = 3). (c) Concanavalin A expanded γδ T cells from four different donors (HD1, 2, 3, and 4) were used in a chromium-release 
assay using Daudi cells as target as in (a) (n = 1). Data represent mean ± SD of triplicate wells. Significance was determined by unpaired t-test, two-tailed between 
untreated γδ T cells and UCHT1, Fab or Fabred-treated samples.
FigUre 6 | Tumor killing by γδ T cells is independent of Nck recruitment to the γδ T cell antigen receptor. 51Cr-labeled Daudi cells were incubated with concanavalin A 
(a) or zoledronate (B) expanded γδ T cells without (−) or with 5 µg/ml UCHT1, 3.33 µg/ml Fab, or 3.33 µg/ml Fabred. In addition, 10 or 100 nM of AX-024 was included 
or not. The effector to target ratio was 12.5:1. After 5 h of co-culture, the amount of released 51Cr was measured in the supernatant by γ-ray spectroscopy. Data 
represent mean ± SD of triplicates (n = 3). Significance was determined by unpaired t-test, two-tailed between untreated samples and samples treated with AX-024.
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Daudi cells in the presence or absence of UCHT1, Fab, or Fabred 
with or without AX-024 to block the PRS–SH3.1 interaction. Two 
concentrations of AX-024 were used, 10 nM AX-024 as in Figure 5 
and 100 nM AX-024. All three anti-CD3 reagents significantly 
enhanced tumor killing by the γδ T cells. AX-024 did not disturb 
the γδ T cell-mediated “basal” tumor cell killing (without anti-
CD3 reagents). Importantly, AX-024 did also not influence the 
enhanced killing activity in the presence of the anti-CD3 reagents 
for the concanavalin A expanded γδ T cells (Figure 6A). In case 
of the zoledronate-expanded γδ T cells (Figure 6B) very small 
reductions with 10  nM, but not with 100  nM AX-024, can be 
detected. Hence, we concluded that AX-024 did also not diminish 
tumor killing for the zoledronate-expanded γδ T cells.
These findings indicate that Nck recruitment to the γδ TCR is 
dispensable for the cytotoxic activity of γδ T cells stimulated by 
tumor cells.
activation of γδ T cells is independent of 
nck recruitment to the γδ Tcr
In addition to cytotoxic activity, γδ T  cell activation involves 
up-regulation of the expression of the high affinity IL-2 receptor 
CD25 and of the activation marker CD69 (46). Next, we sought to 
analyze whether Fab can also enhance these activation events in 
γδ T cells and whether Nck binding to the γδ TCR was required 
for that. Zoledronate-expanded γδ T cells were stimulated with 
Daudi or Raji cells in the presence or absence of UCHT1, Fab, 
or Fabred with or without AX-024. As with tumor cell killing, 
all three anti-CD3 reagents enhanced CD25 (Figures  7A,B) 
or CD69 (Figure 7C) up-regulation by the γδ T cells. Blocking 
the γδ TCR–Nck interaction with AX-024 did neither affect the 
expression of CD25 nor of CD69 independently of the anti-CD3 
reagents (Note that the decrease of UCHT1 enhanced CD69 
expression by AX-024 was not seen in other experiments).
We have also tested whether AX-024 impacts on CD69 up-
regulation in fresh, naive γδ T cells from human blood. As with 
the expanded cells, AX-024 did not change the extent of CD69 
expression when the cells were stimulated with UCHT1 (Figure 
S3 in Supplementary Material).
Furthermore, γδ T cells secrete pro-inflammatory cytokines, 
such as TNFα and IFNγ, upon activation by tumor cells (47). Finally, 
we show that TNFα and IFNγ production induced by Daudi or 
Raji cells was enhanced by UCHT1, Fab, or Fabred (Figures 7D,E). 
AX-024 neither diminished TNFα and IFNγ secretion in the 
absence nor in the presence of the anti-CD3 reagents.
Together, our data indicate that UCHT1, Fab, or Fabred binding 
to the γδ TCR enhances the tumor cell-induced activation of γδ 
T cells. Although Nck is recruited to the anti-CD3 bound γδ TCR, 
this recruitment seems to be dispensable for γδ T cell activation 
events, such as cytotoxicity, CD25, and CD69 up-regulation, as 
well as TNFα and IFNγ secretion.
Fab Fragments enhance intracellular 
signaling independent of the nck-γδ Tcr 
interaction
If Nck recruitment to the γδ TCR is not involved in tumor killing 
and the up-regulation of activation markers, it might also not 
be required for the γδ TCR induced induction of intracellular 
signaling. To test this, we stimulated fresh human γδ T cells with 
UCHT1 in the absence or presence of AX-024 and measured the 
phosphorylation of the kinases ZAP70 and Erk by flow cytometry 
(Figures S4A,B in Supplementary Material). As expected, γδ 
TCR stimulation increased the amount of phospho-ZAP70 and 
phospho-Erk. Importantly, treatment of the cells with AX-024 
did not influence the extent of ZAP70 or Erk phosphorylation, 
indicating that recruitment of Nck to the γδ TCR was not required 
for the induction of signaling by the UCHT1-stimulated γδ TCR.
Next we asked whether Fab fragments would also increase 
signaling by an antigen-triggered γδ TCR. In order to use a cognate 
ligand for the γδ TCR, we switched to a different γδ TCR system, 
namely the G8 γδ TCR where a clearly defined ligand, namely 
MHC class I-like T22, can be used (48, 49). In fact, stimulation 
of G8 γδ TCR-expressing cells with soluble T22 tetramers leads 
to T cell stimulation without stabilizing the CD3 conformational 
change at the γδ TCR (41). Here, we expressed the G8 γδ TCR in 
Jurkat T cells, similar to as we did with a chimeric γδ TCR in a 
Jurkat-derived cell (27). Indeed, the G8 γδ TCR was expressed on 
the surface of the Jurakt cells (Figure 8A).
Next, we stimulated the G8 γδ TCR-expressing Jurkat cells with 
soluble T22 tetramers and measured the amount of intracellular 
calcium as a signaling read-out. As expected, the Fab fragments 
hardly induced calcium signaling downstream of the γδ TCR, 
whereas T22 tetramers did (Figure 8B). Importantly, adding Fab 
to the T22 tetramers augmented the calcium response, most likely 
by stabilizing the γδ TCR in the active CD3 conformation. The 
same result was obtained when using Fabred fragments (Figure 
S5A in Supplementary Material).
To test whether the enhanced calcium response was sensitive 
to the recruitment of Nck to the γδ TCR, we stimulated the G8 
γδ TCR-expressing Jurkat cells with the T22 tetramers and Fab 
in the absence or presence of AX-024. Clearly, AX-024 treatment 
did reduce the calcium response (Figure 8C), suggesting that the 
Nck–γδ TCR interaction was not required for the enhanced cal-
cium signaling. The same result was obtained when using Fabred 
fragments (Figure S5B in Supplementary Material).
Together our data suggest that Fab fragments enhance signal-
ing via the γδ TCR by stabilizing the active CD3 conformation, 
independent of the Nck–γδ TCR interaction.
DiscUssiOn
The potential use of cytotoxic γδ T cells in immunotherapy against 
cancer is particularly attractive. Since γδ T cells are independent 
of antigen presentation by MHC class I and of the presence of 
mutated epitopes, they are ideal effectors against tumors with low 
mutation loads. Cytotoxic γδ T  cells display afferent responses 
and have been recognized as the best favorable prognosis marker 
for solid tumors when infiltrated immune cells were analyzed 
(50). This suggested that γδ T cells play an important role in the 
defense against tumors in human patients. Therefore, γδ T cells 
are currently tested as cellular reagents in cancer immunotherapy 
clinical trials (51–53).
We have previously shown that the tumor killing activity of γδ 
T  cells can be increased by addition of the anti-CD3ε antibody 
FigUre 7 | The up-regulation of activation markers and cytokines is independent of Nck recruitment to the γδ T cell antigen receptor (TCR). Daudi and Raji cells 
were incubated with zoledronate-expanded γδ T cells without (−) or with 5 µg/ml UCHT1, 3.33 µg/ml Fab, or 3.33 µg/ml Fabred. In addition, 10 nM AX-024 was 
included or not. The γδ T cell to target cell ratio was 12.5:1. The cells were co-cultured at 37°C and 5% CO2 for 18 h. Subsequently, cells were either stained with 
anti-CD25 and anti-γ/δTCR (a,B) or with anti-CD69 and anti-γ/δTCR (c) antibodies. Fluorescence intensities were quantified by flow cytometry (a) and the mean 
fluorescence intensity is displayed (B,c). Data represent mean ± SD of triplicates (n = 3). Significance was determined by unpaired t-test, two-tailed between 
untreated samples and samples treated with AX-024. (D,e) The experiments were performed as in (a). After co-culturing of the cells for 18 h, the supernatants  
were harvested. TNFα (D) and IFNγ (e) concentrations were quantified by enzyme linked immunosorbent assay.
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UCHT1. However, UCHT1 is a potent T cell activating agent due 
to its intrinsic capability to induce cross-linking of TCRs and to 
stabilize the active CD3 conformation (27, 41). Thus, UCHT1 acti-
vates all T cells (αβ and γδ), regardless of their specificity, possibly 
resulting in an unspecific polyclonal T cell response and a potential 
life-threatening cytokine storm. These drawbacks profoundly limit 
the use of UCHT1 as a therapeutical agent to enhance tumor cell 
killing by cytotoxic γδ T cells that recognize tumor antigens by 
their γδ TCR. Here, we aimed to explore the use of UCHT1 Fab 
fragments as an alternative to enhance tumor killing by γδ T cells. 
UCHT1 Fab fragments do not activate αβ TCRs by themselves due 
to their monovalent binding (30, 38, 39) and here we show that this 
is also the case with the γδ TCR. Importantly, we demonstrate that 
UCHT1 Fab fragments significantly boosted tumor cell killing by 
γδ T cells, suggesting the use of UCHT1 Fab fragments as specific 
co-stimulation agents in γδ T cell immunotherapy approaches.
All three ligands that were previously tested for the γδ TCR 
(Daudi and phosphoantigens for the human Vγ9Vδ2 TCR and 
FigUre 8 | Calcium signaling is enhanced by Fab fragments and does not require the Nck-γδ T cell antigen receptor (TCR) interaction. (a) G8 γδ TCR-expressing 
Jurkat cells were stained with the γδ TCR-specific antibody GL3 and analyzed by flow cytometry. As controls, the GL3-stained parental Jurkat cells and unstained 
G8 γδ TCR-expressing cells are shown (n > 3). (B) Jurkat cells expressing the G8 γδ TCR were stimulated with the G8 ligand T22 tetramers (T22t), UCHT1 Fab,  
or a combination of both T22t and Fab. Intracellular calcium was measured using the dyes Fluo-3 and Fura-red by flow cytometry. Calcium influx is depicted as  
the median ratio of Fluo-3 to Fura-red fluorescence over time. As a negative control, steptavidin was added to the cells. The arrow indicates addition of the stimuli 
(n = 3). (c) The experiment was performed as in (c) with the difference that cells without and with 10 nM AX-024 were stimulated with the combination of T22t and 
Fab. As a control, PBS was added to the cells (n = 3).
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T22 tetramers for the murine G8 TCR) did not stabilize the active 
CD3 conformation, as defined by the exposure of the CD3ε PRS 
(41). In contrast, UCHT1 did stabilize the γδ TCR in its active 
conformation (41). In addition, UCHT1 binds simultaneously to 
two TCRs and thereby crosslinks γδ TCRs, leading to γδ TCR 
and T cell activation. Thus, by using UCHT1, it is not possible 
to distinguish whether cross-linking of TCRs or stabilization of 
the CD3 active conformation is the event enhancing tumor kill-
ing by γδ T cells. To answer this mechanistic question, we used 
here monovalent UCHT1 Fab fragments, which only have one 
binding site per molecule and, therefore, do not cross-link TCRs. 
Our data show that UCHT1 Fab fragments also enhanced the 
cytotoxic activity of human γδ T cells. Thus, a cross-linking activ-
ity is not required to boost γδ T cell cytotoxic activity. We next 
tested whether UCHT1 Fab fragments also stabilize the active γδ 
CD3 conformation and thereby, induce the recruitment of Nck 
to the CD3ε PRS. The treatment of the γδ T cells with the Fab 
fragments or with UCHT1 led to the recruitment of Nck to the 
γδ TCR. This induced recruitment was abrogated in the presence 
of the inhibitor AX-024, which blocks the interaction of the CD3ε 
PRS with SH3.1(Nck) (36). And indeed SH3.1(Nck) can bind to 
the CD3ε PRS in γδ TCRs [(41) and this study]. These data pro-
vide strong mechanistic evidence demonstrating that Nck binds 
to the γδ TCR via the CD3ε PRS upon stabilization of the active 
CD3 conformation, like in the αβ TCR (26, 33).
Human Vγ9Vδ2 γδ T  cells modestly killed the B  cell lym-
phoma lines Daudi and Raji. This killing was enhanced in the 
presence of UCHT1 Fab. Daudi and other tumor cells express 
high levels of phosphoantigens (14), which together with buty-
rophilin 3A1 most likely constitute (part of) the ligand for the 
Vγ9Vδ2 TCR (24, 25). Thus, the γδ TCR was likely to be bound 
to the natural phosphoantigen/butyrophilin 3A1 ligand in our 
experimental settings. This potential binding stimulated the 
γδ TCR, but without stabilizing the γδ TCR in its active CD3 
conformation (41). Here, we show that, in addition to stimu-
lation by the natural ligands, the γδ TCR was stabilized in its 
active conformation when we used the UCHT1 Fab fragments. 
This treatment not only enhance the tumor cell killing, but also 
the activation of γδ T cells as seen by augmented CD69, CD25, 
IFNγ, and TNFα expression. Enhanced up-regulation of CD69 
and CD25 was also seen with the complete UCHT1 antibody 
( (41) and this study). However, increased production of IFNγ 
and TNFα by UCHT1 was not seen earlier (41) and this could 
be due to differences in the cells used (expanded γδ T  cells 
versus a γδ T cell clone). Our data thus support the idea that 
enforcing the γδ TCR to adopt the active CD3 conformation in 
the presence of its natural ligand might generate a quantitatively 
or/and qualitatively distinct set of activation signals that ulti-
mately enhance γδ T cell activation.
One mechanism to promote such distinct signals might have 
been the recruitment of Nck to the γδ TCR. We found, however, 
that Nck recruitment was dispensable for the enhanced activa-
tion of the γδ T cells in the presence of the Fab fragments or the 
complete antibody. This suggests that a so far unknown effect of 
the active CD3 conformation in the γδ TCR increases γδ T cell 
activity. One possibility might be enhanced phosphorylation of 
the CD3 tails on tyrosines in analogy to the αβ TCR (27, 28), 
which might lead to a stronger T cell stimulation. Indeed, the 
kinase ZAP70 that binds to doubly phosphorylated CD3 subu-
nits (54) and is recruited to the γδ TCR (55) was phosphorylated 
upon stimulation of γδ T  cells with UCHT1. Since this phos-
phorylation was independent of Nck recruitment, it might be a 
downstream effect of the active CD3 conformation that we were 
looking for.
ZAP70 is important to trigger signaling cascades in αβ T cells, 
such as the Erk and calcium pathways (54), and these pathways 
are also triggered by stimulation of the Vγ9Vδ2 TCR by phospho-
antigens or anti-CD3 antibodies (41, 55–59). Here, we show that 
calcium influx stimulated by the cognate ligand–γδ TCR interac-
tion was increased upon stabilization of the active CD3 confor-
mation. This is in line with our earlier finding that trapping the 
γδ TCR in the resting CD3 conformation by using CD3ε mutants 
[CD3εK76T and CD3εC80G (31, 32)] reduced γδ TCR calcium 
signaling (41). Similarly UCHT1 enhanced phosphorylation of 
Erk [(41) and this study], and this again was independent of Nck 
recruitment to the γδ TCR. Since the Erk pathway is involved 
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in the antitumor activity of Vγ9Vδ2 T cells (56), an increase in 
phospho-Erk might explain the enhanced tumor killing when the 
active CD3 conformation was stabilized. In conclusion, stabiliza-
tion of the active CD3 conformation in a ligand-triggered γδ TCR 
leads to enhanced downstream signaling.
Taken together, this study might help to design therapeuti-
cal agents, such as the Fab fragments of UCHT1, to specifically 
enhance tumor cell killing by γδ T cells while preventing unspe-
cific activation of all T cells.
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